![]() ![]() ![]() Because dabigatran etexilate is excreted predominantly by the kidneys, adequate diuresis must be maintained. General supportive measures such as surgical haemostasis and blood volume replacement should be carried out. In the event of haemorrhagic complications, treatment must be stopped and the source of bleeding investigated. The dabigatran etexilate summary of product characteristics states that excessive anticoagulation may require dabigatran etexilate treatment to be stopped. Antidotes for the other licensed NOACs are in development but are not currently available (April 2016). Idarucizumab is the first agent to be licensed to reverse the anticoagulant effect of a NOAC, and it is a specific reversal agent for dabigatran etexilate. Until recently, there were no specific antidotes for the NOACs unlike warfarin. The most common adverse effect of anticoagulants is bleeding, ranging from mild events to serious and fatal haemorrhage. Licensed oral anticoagulants that are used in the UK include warfarin, and the non‑vitamin K antagonist oral anticoagulants (NOACs) apixaban, dabigatran etexilate, edoxaban and rivaroxaban. Anticoagulant therapy is used for preventing and treating thromboembolism across various clinical indications. ![]()
0 Comments
Leave a Reply. |